Biological psychiatry global open science · 2026
Cerebrospinal Fluid Neuromarker Levels in Patients With Schizophrenia and Healthy Control Participants: A Proximity Extension Assay Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hidese Shinsuke, Hattori Kotaro, Enokida Takako, Tatsumi Megumi, Matsumura Ryo, Kunugi Hiroshi
Аннотация
BACKGROUND: To further evaluate the association between cerebrospinal fluid (CSF) neuromarkers and schizophrenia, we measured CSF neuromarker levels using proximity extension assay (PEA) in patients with schizophrenia and healthy control (HC) participants.
METHODS: Participants included 97 patients with schizophrenia (mean age [SD] = 38.8 [10.3] years; 60 men and 37 women) and 71 HC participants (mean age [SD] = 46.9 [15.4] years; 42 men and 29 women). Symptoms in patients with schizophrenia were assessed using the Positive and Negative Syndrome Scale (PANSS). CSF protein levels were measured using the Olink PEA Neurology Panel.
RESULTS: CSF levels of cadherin 3, FcRL2, granzyme A, NAAA, plexin-B1, and sFRP-3 were lower in patients with schizophrenia than in HC participants (p < .05). Levels of BCAN, beta-NGF, carboxypeptidases A2 and M, CD200, DDR1, GDF-8, MANF, MDGA1, NAAA, neprilysin, neuropilin-2, neutral ceramidase, Nr-CAM, NTRK2, NTRK3, PDGF-R-alpha, plexin-B3, RGMA, ROBO2, testican-1, THY1, and WFIKKN1 positively correlated with PANSS positive scores, whereas protogenin levels negatively correlated with PANSS negative and general psychopathology scores in patients with schizophrenia (p < .05).
CONCLUSIONS: This PEA study identified candidate CSF trait and state markers in schizophrenia; however, these findings require confirmation in further studies, as this was a primarily exploratory and hypothesis-generating study.
METHODS: Participants included 97 patients with schizophrenia (mean age [SD] = 38.8 [10.3] years; 60 men and 37 women) and 71 HC participants (mean age [SD] = 46.9 [15.4] years; 42 men and 29 women). Symptoms in patients with schizophrenia were assessed using the Positive and Negative Syndrome Scale (PANSS). CSF protein levels were measured using the Olink PEA Neurology Panel.
RESULTS: CSF levels of cadherin 3, FcRL2, granzyme A, NAAA, plexin-B1, and sFRP-3 were lower in patients with schizophrenia than in HC participants (p < .05). Levels of BCAN, beta-NGF, carboxypeptidases A2 and M, CD200, DDR1, GDF-8, MANF, MDGA1, NAAA, neprilysin, neuropilin-2, neutral ceramidase, Nr-CAM, NTRK2, NTRK3, PDGF-R-alpha, plexin-B3, RGMA, ROBO2, testican-1, THY1, and WFIKKN1 positively correlated with PANSS positive scores, whereas protogenin levels negatively correlated with PANSS negative and general psychopathology scores in patients with schizophrenia (p < .05).
CONCLUSIONS: This PEA study identified candidate CSF trait and state markers in schizophrenia; however, these findings require confirmation in further studies, as this was a primarily exploratory and hypothesis-generating study.